European hospitals may be inadequate to support continuity of care.
Background
Interventions aimed at improving the quality of antibiotic prescribing can be targeted more effectively if we have deeper knowledge about where the efforts should be focused. The aim of this study was to analyse and compare the quality of outpatient antibiotic prescribing in Denmark and Aragó n, a Northeastern Spanish region. Methods Outpatient antibiotic prescribing data (2010) were obtained from the National Institute for Health Data and Disease Control in Denmark and the Information System on Medication Consumption in Aragó n. The number of defined daily dose (DDD) of the different substances was counted. The analysis of antibiotic prescribing was carried out according to the Drug Utilization 90% (DU90%) approach and the European Surveillance of Antimicrobial Consumption (ESAC) quality indicators for outpatient antibiotic use.
Results
The bulk of prescription (90% of total DDD) consisted of 14 (out of 39) different antibiotics in Denmark, ranking first narrow-spectrum penicillins. In Aragó n, 11 (out of 59) different substances accounted for the DU90%, mainly broad-spectrum penicillins. ESAC quality indicators indicated a high antibiotic consumption (23.15 DID) and important seasonal variation of use in Aragó n, reflecting an overuse and misuse according to current guidelines. In Denmark, obtained data revealed a moderate utilization (17.00 DID), with a prescribing pattern that shows a better compliance with recommendations. Conclusions There are notable differences in relation to quantity and quality of outpatient antibiotic prescribing between the two studied areas. It is necessary to make general population as well as healthcare professionals aware of the need for responsible use of these drugs. Complying with international recommendations and adapting them, in any case, to the local context, is required.
Key messages
There are remarkable differences between European countries as far as the quality of outpatient antibiotic prescribing is concerned. Enhancing interventions to promote a rational use of these drugs is necessary; in other words, making an important effort at a local level to avoid a global public health problem. A systematic random sample was drawn up from routine databases and patients (n = 30), who received care in Malta or in London during the year 2012, participated in face-to-face or telephone semi-structured interviews. During the interviews, it was noted that several patients who were referred to the United Kingdom for therapy had previously received treatment in Malta which created a new patient group. The data collected were analysed qualitatively by a thematic data analysis and a SWOT analysis. Findings suggest that patients who received care domestically benefited from being treated in a familiar setting and close to their relatives. Patients who were referred to the United Kingdom have positive experiences of receiving care in a highly specialized cancer hospital. However, these patients faced financial, information provision and follow-up hurdles and the lack of proximity from home also tended to have an impact on their experiences. The study elicited insight on patients' perceptions of crossborder cancer care and stimulated dialogue among stakeholders on how inter-relationships among patients, health professionals and the healthcare system reflect patient care experiences. A debriefing session was organized for practitioners and health authorities to disseminate the findings and discuss patient views of domestic and cross-border cancer care. It is being recommended that within the long standing MaltaUnited Kingdom collaboration for specialized cross-border care, patient experiences are optimized in light of the patientcentered approach endorsed by the EU Patients' Rights directive.
Patients should be at the heart of healthcare systems. By capturing true patient experiences of cross-border care as opposed to care at home, improvements can be made to cross-border care delivery. This study will not only benefit health professionals and providers but patients themselves who are referred to similar treatment in the future. Background Several high profile cases of medical malpractice have raised concerns about the management by regulatory bodies of the performance of doctors working outside their native country within Europe. This paper will assess the roles of and consistencies between regulatory bodies in nine European countries on how they regulate quality of health care and patient safety. 
